【摘要】 mi RNA是一类内源性的非编码小分子RNA,具有高度保守性,参与多种人类肿瘤的发生、发展,其中也包括甲状腺癌。与分化型甲状腺癌比较,未分化型甲状腺癌的预后较差,这可能与其有较高比例的肿瘤干细胞有关。mi R-200c作为一个新发现的抑癌因子,可抑制甲状腺癌细胞的增殖,促进其凋亡,并可通过转化生长因子-β(TGF-β)通路、表皮生长因子受体(EGFR)通路等对上皮-间充质转化过程进行调控,而近期的研究发现,上皮-间充质转化是肿瘤干细胞形成的驱动力。因此,mi R-200c可能成为难治性甲状腺癌治疗上的一个潜在靶点。本文就mi R-200c在甲状腺癌的研究进展进行综述。更多还原

【Abstract】 miRNA is a kind of endogenous, non-coding small molecule RNA, which is highly conserved and related to the occurrence and development of various human tumors including thyroid cancer. Compared with differentiated thyroid cancer, the prognosis of undifferentiated thyroid cancer is worse, which may be associated with a higher proportion of cancer stem cells. miR-200 c, as a novel tumor suppressor, can inhibit the proliferation of thyroid cancer cells and promote their apoptosis. Moreover, miR-200 c can modulate epithelial-mesenchymal transition through transforming growth factor-β(TGF-β) pathway and epidermal growth factor receptor(EGFR) pathway. Recent researches have found that epithelial-mesenchymal transition induces the formation of cancer stem cell. Hence, miR-200 c may serve as a potential molecular target for biological treatment of refractory thyroid cancer. The research progress in the relationship between miR-200 c and thyroid cancer is reviewed in this paper.更多还原